We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-8.83%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$3.57B
AUM Growth
-$614M
Cap. Flow
+$51.4M
Cap. Flow %
1.44%
Top 10 Hldgs %
48.82%
Holding
78
New
14
Increased
15
Reduced
33
Closed
9

Top Buys

1
BEAM icon
Beam Therapeutics
BEAM
+$73M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$72.6M
3
ONEM
1Life Healthcare
ONEM
+$68.5M
4
MRK icon
Merck
MRK
+$64.9M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$53.9M

Top Sells

1
BMY icon
Bristol-Myers Squibb
BMY
+$116M
2
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$109M
3
BSX icon
Boston Scientific
BSX
+$73.8M
4
CNC icon
Centene
CNC
+$44.2M
5
HCA icon
HCA Healthcare
HCA
+$42.2M

Sector Composition

1 Healthcare 97.84%
2 Industrials 0.87%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCDA
26
DELISTED
Tricida, Inc. Common Stock
TCDA
$46.8M 1.31%
2,126,600
-2,500
-0.1% -$80.3K
NGNE icon
27
Neurogene
NGNE
$744M
$46M 1.29%
202,061
+106,019
+110% +$21.8M
KRYS icon
28
Krystal Biotech
KRYS
$10.5B
$45.5M 1.28%
1,051,800
-38,400
-4% -$2.01M
ATRA icon
29
Atara Biotherapeutics
ATRA
$75.6M
$45M 1.26%
211,735
+25,792
+14% +$8.19M
AXNX
30
DELISTED
Axonics, Inc. Common Stock
AXNX
$38.3M 1.07%
1,507,400
-24,600
-2% -$732K
PRAH
31
DELISTED
PRA Health Sciences, Inc.
PRAH
$36.8M 1.03%
442,700
-7,100
-2% -$692K
SRRK icon
32
Scholar Rock
SRRK
$6.33B
$35M 0.98%
2,890,089
-50,800
-2% -$683K
DXCM icon
33
DexCom
DXCM
$29.6B
$34.8M 0.98%
+517,200
New +$32.2M
EIDX
34
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$33.8M 0.95%
689,478
-11,700
-2% -$596K
GMAB icon
35
Genmab
GMAB
$17.6B
$32.8M 0.92%
1,549,000
+612,300
+65% +$13.6M
AMED
36
DELISTED
Amedisys
AMED
$32.6M 0.91%
177,565
-3,500
-2% -$623K
CYRX icon
37
CryoPort
CYRX
$832M
$31M 0.87%
1,817,663
+975,300
+116% +$17.1M
ZYME icon
38
Zymeworks
ZYME
$1.78B
$30.8M 0.86%
+868,600
New +$35.5M
REPL icon
39
Replimune Group
REPL
$859M
$29.7M 0.83%
2,980,493
+214,086
+8% +$3.19M
WVE icon
40
Wave Life Sciences
WVE
$1.12B
$27.4M 0.77%
2,927,352
-399,141
-12% -$3.4M
CTLT
41
DELISTED
CATALENT, INC.
CTLT
$26.3M 0.74%
+506,300
New +$27.6M
PPD
42
DELISTED
PPD, Inc. Common Stock
PPD
$23M 0.64%
+1,290,832
New +$32.4M
ARDX icon
43
Ardelyx
ARDX
$1.28B
$22.2M 0.62%
3,904,100
-95,900
-2% -$652K
ODT
44
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$19.5M 0.55%
708,038
-82,033
-10% -$2.39M
BCEL
45
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$18.7M 0.52%
1,128,806
-8,000
-0.7% -$145K
SWAV
46
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$18.5M 0.52%
557,800
-10,100
-2% -$401K
TWST icon
47
Twist Bioscience
TWST
$5.84B
$18M 0.51%
+590,200
New +$15.9M
GRTS
48
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$17.9M 0.5%
3,068,194
-48,400
-2% -$406K
HOOK
49
DELISTED
HOOKIPA Pharma
HOOK
$15.4M 0.43%
186,251
-3,001
-2% -$329K
TCRR
50
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$13.7M 0.38%
1,767,288
-31,900
-2% -$390K
1
2
3 4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2020 Portfolio in Review

As of Q1 2020, Redmile Group held 78 positions worth $3.57B, down 15% from $4.18B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q1 2020 filing shows 14 new, 15 increased, 33 reduced and 9 closed positions. Its largest new stake was Beam Therapeutics: 3,359,258 shares worth $60.5M. The largest sale was Bristol-Myers Squibb, an estimated $116M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials and Technology.

  • Redmile Group's largest Q1 2020 buy was Beam Therapeutics: 3,359,258 shares worth $60.5M.
  • Redmile Group added most to Momenta Pharmaceuticals, Inc. in Q1 2020, an estimated $53.9M increase.
  • Redmile Group's biggest Q1 2020 reduction was Centene, cutting an estimated $44.2M.
  • Redmile Group fully exited Bristol-Myers Squibb in Q1 2020, selling an estimated $116M.
  • Redmile Group's ten largest holdings make up 49% of its $3.57B portfolio in Q1 2020.
  • Redmile Group opened 14 new positions and closed 9 in Q1 2020.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $3.57B.

Based on Redmile Group's 13F filing for Q1 2020, filed 15 May 2020.